l e t t e r s 7 6 VOLUME 21 | NUMBER 1 | JANUARY 2015 nature medicine A key determinant of geriatric frailty is sarcopenia, the age-associated loss of skeletal muscle mass and strength 1,2 .
A key determinant of geriatric frailty is sarcopenia, the age-associated loss of skeletal muscle mass and strength 1,2 . Although the etiology of sarcopenia is unknown, the correlation during aging between the loss of activity of satellite cells, which are endogenous muscle stem cells, and impaired muscle regenerative capacity has led to the hypothesis that the loss of satellite cell activity is also a cause of sarcopenia 3, 4 . We tested this hypothesis in male sedentary mice by experimentally depleting satellite cells in young adult animals to a degree sufficient to impair regeneration throughout the rest of their lives. A detailed analysis of multiple muscles harvested at various time points during aging in different cohorts of these mice showed that the muscles were of normal size, despite low regenerative capacity, but did have increased fibrosis. These results suggest that lifelong reduction of satellite cells neither accelerated nor exacerbated sarcopenia and that satellite cells did not contribute to the maintenance of muscle size or fiber type composition during aging, but that their loss may contribute to age-related muscle fibrosis.
Recent estimates indicate that up to one-third of elderly people suffer from frailty, characterized by a common set of symptoms including loss of muscle strength, increased fatigability, modest levels of physical activity and decreased body weight 1 . The close relationship between frailty and defects in the musculoskeletal system suggests sarcopenia is a crucial factor in the emergence of geriatric frailty, thus limiting the ability to perform activities of daily living and significantly increasing the risk of falling 5, 6 .
Numerous studies in humans and rodents report a strong correlation between the loss and dysfunction of satellite cells and sarcopenia 3, 4 . Motivated by the idea that the restoration of satellite cell activity will provide a therapeutic basis for treating sarcopenia, a great deal of effort has gone into defining the environmental and cellular changes underlying the loss in satellite cell activity with age [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Despite the correlation between declining satellite cell-dependent regenerative capacity and age, no studies to date have tested this relationship directly to determine whether the loss of satellite cell activity causes sarcopenia. We recently developed a genetic mouse model that allows for the specific, inducible depletion of satellite cells in adult skeletal muscle [19] [20] [21] . The Pax7 CreER/+ ;Rosa26 DTA/+ (here referred to as Pax7 CreER -DTA) strain was generated by crossing Pax7 CreER/CreER and Rosa26 DTA/DTA strains. Treatment of Pax7 CreER -DTA mice with tamoxifen activates Pax7 promoter-driven Cre recombinase only in satellite cells, which activates the gene encoding diphtheria toxin A (DTA) and results in the killing of satellite cells 21 . We took advantage of this mouse model to directly test the hypothesis that loss of satellite cells, which underlies the well-documented impairment in muscle regenerative capacity [21] [22] [23] [24] , in young adult animals results in muscle wasting with advancing age. If there is a causal relationship between the loss of satellite cell activity and sarcopenia, then we would predict accelerated and exacerbated sarcopenia in muscle with a significantly reduced complement of satellite cells.
We administered vehicle or tamoxifen by intraperitoneal injection to adult (4 months old) male Pax7 CreER -DTA mice for 5 consecutive days to effectively deplete satellite cells (Fig. 1) and then allowed the mice to age naturally. Approximately 1 year later, we analyzed a subset of these mice (aged 16-18 months, termed middle aged (MA)) and found that satellite cell numbers did not recover over time. Consistent with previous studies 21, 23 , in muscles that remained substantially depleted (>85% relative to vehicle-treated control mice) of satellite cells, muscle regeneration after injury induced by BaCl 2 injection was severely impaired (Fig. 2a) . No loss of muscle mass was apparent in hind limb muscle of vehicle-or tamoxifen-treated MA mice except in the soleus muscle (Fig. 2b) ; however, significant atrophy was apparent in 24-month-old mice (designated as the 'aged' group) in both vehicle-and tamoxifen-treated mice (Fig. 2b) . Aged vehicle-treated mice had a median lifespan of 23.9 months and a maximum lifespan of 24.6 months; aged tamoxifen-treated mice had a median lifespan of 22.6 months and a maximum lifespan of 24.4 months. Decrements in hind limb muscle mass in the aged mice met criteria for sarcopenia in humans 25 ; that is, appendicular muscle mass was 2 s.d. below that of younger mice (5 months old, Inducible depletion of satellite cells in adult, sedentary mice impairs muscle regenerative capacity without affecting sarcopenia designated as the 'young' group). These data suggest that loss of satellite cell-dependent regenerative capacity throughout adulthood does not accelerate sarcopenia in aging mice.
We next determined whether features of sarcopenia were exacerbated in aged mice owing to a lifetime reduction of satellite cells. Analysis of satellite cell abundance in vehicle-treated mice 1 month after injection (young) and 20 months after injection (aged) (Fig. 1a,b) showed a substantial age-associated reduction in satellite cells (Fig. 1b) . Tamoxifen administration accelerated this cell loss and resulted in >94% reduction in satellite cells (compared to muscle from vehicle-treated mice) in multiple hind limb muscles 1 month after injection (young), with little recovery in satellite cells per myofiber occurring even after 20 months (aged) (Fig. 1b) ; on average, satellite cells remained 83% depleted in aged mice (range 64-87%), well below the loss normally associated with aging. Despite the reduction in satellite cell abundance to a degree often associated with severely impaired muscle regeneration, age-associated muscle atrophy, as indicated by changes in both muscle wet weight ( Fig. 2b ) and mean myofiber crosssectional area (CSA) (Fig. 1c) , occurred to the same extent in all hind limb muscles from both vehicle-treated and satellite cell-depleted mice. Myofiber CSA analyzed by fiber type (Fig. 3) showed agerelated atrophy in all muscles except the soleus, which has a higher proportion of slow-twitch fibers (Fig. 3c) . In agreement with the well-characterized atrophy of the largest, fast-twitch glycolytic fibers with age 26 , type 2b fibers showed the greatest degree of atrophy that appeared unaffected by satellite cell abundance (Fig. 3c) . Moreover, myofiber size distribution across hind limb muscles showed the characteristic leftward shift owing to overall higher abundance of smaller fibers with age in both treatment groups (Supplementary Fig. 1 ). Satellite cell depletion also showed no significant effect on fiber npg type distribution ( Supplementary Fig. 2) ; at 24 months, only the plantaris and soleus muscles showed an age-dependent shift in the relative frequency of different fast-twitch (type 2) fibers that was independent of satellite cell abundance. In addition to atrophy of individual myofibers, a decline in the number of myofibers and a reduction in single fiber-specific force generation (force per unit area) are associated with sarcopenia. We measured these characteristics in the plantaris muscle, as it showed little recovery of satellite cells with age and was therefore most severely depleted (Fig. 1b) . We did not observe a loss of myofibers at 24 months in either vehicle-or tamoxifen-treated mice (Fig. 4a) . Analyses of isolated myofibers (Fig. 4b) showed that the number of myonuclei per 100 µm of myofiber length was not changed with age (Fig. 4c) . We performed myonuclear counts on single, fixed myofibers of intermediate size (1,000-2,500 µm 2 ), which make up greater than 80% of all myofibers, and our results were consistent with a recent study reporting no myonuclear loss with age in fibers in this size range 27 . Moreover, myonuclear number appeared to be unaffected by depletion of satellite cells (Fig. 4c) , suggesting that the maintenance of myonuclei is not linked to satellite cell abundance. This conclusion was further supported by analysis of BrdU-labeled myonuclei (Fig. 4d) . We provided mice with BrdU via drinking water for 2 weeks to identify nuclei that had undergone DNA replication, then killed the mice and quantified fusion of labeled nuclei into myofibers. Although myonuclear addition was very infrequent during the 2-week labeling (approximately 0.1% of myofibers from vehicle-treated young and aged mice contained a labeled myonucleus), no labeled myonuclei were detected in plantaris muscle after tamoxifen treatment (Fig. 4d) . Finally, myofiber-specific force was reduced 31% with age (aged versus young) (Fig. 4e) , comparable to the force decrement reported in myofibers isolated from adult humans aged 65-85 years using a similar permeabilized fiber preparation 28 ; however, the decrease in specific force did not seem to be affected by satellite cell abundance. We also functionally tested single myofibers from the extensor digitorum longus (EDL) muscle from tamoxifen-or vehicle-treated aged mice (Supplementary Fig. 3a-c) . As with the plantaris muscle, no differences in specific or absolute force or single-fiber CSA were apparent as a result of satellite cell depletion in the EDL. Further, overall loss of function with age, as measured by grip strength, was not altered by satellite cell depletion (Supplementary Fig. 3d ). The loss of 45-59% raw grip strength in the aged mice (compared to the young group) did not differ with treatment and is consistent with loss reported in humans with age 29, 30 .
Although age-related myofiber atrophy and weakness were not altered by lifelong satellite cell reduction, we observed a change in the muscle fiber environment. Extracellular matrix (ECM) surrounding myofibers, quantified by Sirius Red staining of collagens, was higher with age and reduced satellite cell content in the plantaris muscle (Fig. 4f-h) . We also assessed ECM accumulation via wheat germ agglutinin (WGA) staining of glycosaminoglycans, which showed that this component of the ECM was also more abundant with age and satellite cell depletion (Supplementary Fig. 4a-c) WGA staining of other hind limb muscles showed excess accumulation of ECM with age that was further exacerbated by a reduction in satellite cell content specifically in the plantaris and tibialis anterior-EDL complex (TA/EDL) muscles (Supplementary Fig. 4c ). These observations support our recent findings that satellite cells regulate the myofiber environment by signaling to fibroblasts 19 . Although our previous work illustrated an additive effect of satellite cell depletion and functional overload on ECM deposition in young adult mice 19 , the present study shows that long-term depletion of satellite cells in (c) Quantification of mean CSA by fiber type in the hind limb muscles. Mean CSA is provided for fiber types that comprise ≥2% of total fibers in a given muscle (see Supplementary Fig. 1b for fiber type frequencies). Data represent mean ± s.e.m. † P < 0.05, aged vs. young mice; ‡ P < 0.05, aged vs. MA mice; # P < 0.05, MA vs. young mice; independent of treatment, two-factor ANOVA. n = 8 (young, vehicle); 8 (young, tamoxifen); 4 (MA, vehicle); 5 (MA, tamoxifen); 7 (aged, vehicle) or 8 (aged, tamoxifen) mice.
npg sedentary mice contributes to dysregulation of the ECM in old age. Moreover, the present work extends previous findings to suggest that satellite cells limit fibrosis preferentially in fast muscles 31 . In summary, although the understanding of satellite cell function in muscle regeneration continues to be refined, our results suggest that the loss of satellite cell-dependent regenerative capacity neither accelerates nor exacerbates sarcopenia. Moreover, our findings have broader implications for the study of tissue homeostasis by showing that skeletal muscle, much like the pancreas, kidney and liver, apparently employs cellular mechanisms that do not necessarily require stem cell participation for tissue maintenance under nonstress conditions [32] [33] [34] [35] . However, the loss of satellite cells may adversely affect overall muscle quality, potentially contributing to the increase in fibrosis observed in aged skeletal muscle 12 . One limitation of the current findings stems from the sedentary nature of the mice. The satellite cell requirement for muscle maintenance in more physically active mice remains to be determined; however, the sedentary nature of the mice in the current study is reflective of low physical activity levels of older adults in the United States 36 .
The findings of the current study have clinical importance, as they draw a clear distinction between therapeutic strategies involving replenishment of muscle satellite cells that may effectively treat degenerative myopathies, such as dystrophies 37 and cachexia 38 , and those that treat sarcopenia. Although degenerative conditions are likely to benefit from a satellite cell-based therapy, our results support a recent review's conclusion 39 that treatment for sarcopenia should focus on the myofiber and motor neuron.
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